Literature DB >> 2868158

Tumor location and drug targeting using a monoclonal antibody (anti-SSEA-1) and antigen-binding fragments.

B Ballou, J M Reiland, G Levine, R J Taylor, W C Shen, H J Ryser, D Solter, T R Hakala.   

Abstract

Both murine and heterotransplanted human nonseminomatous germ-cell tumors have been successfully located by external scintigraphy using radioiodinated anti-SSEA-1, a monoclonal IgM, and its pepsin-derived antigen-binding fragment, F(ab')2 mu. Antibody localization in the tumor is mainly due to antigenic specificity, rather than to nonspecific trapping, and depends strongly on the amount of time after injection. The antibody has been used for drug targeting in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868158     DOI: 10.1002/jso.2930310102

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

2.  In vivo antitumor effect of methotrexate conjugated to a monoclonal IgM antibody specific for stage-specific embryonic antigen-1, on MH-15 mouse teratocarcinoma.

Authors:  S Persiani; B Ballou; W C Shen; H J Ryser; J M Reiland; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: anti-SSEA-1 and MOPC 104E in mouse teratocarcinomas and normal tissues.

Authors:  B Ballou; R Jaffe; S Persiani; W C Shen; J J Langone; H Sands; J M Reilandu; J Curley; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Tumor labeling in vivo using cyanine-conjugated monoclonal antibodies.

Authors:  B Ballou; G W Fisher; A S Waggoner; D L Farkas; J M Reiland; R Jaffe; R B Mujumdar; S R Mujumdar; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.